The MSI subtype, which is identical in both major classification systems, showed a significantly higher mutation rate (excluding the subtype defining TP53 mutations) compared to the microsatellite stable GACs (2.3 vs. 0.4 per tumor; p < 0.001). This evidence concerns the gene TP53 and neoplasm.